Medtronic Debuts MiniMed Go Smart MDI With Simplera Sensor in Europe

Medtronic plc MDT recently announced the commercial launch of the MiniMed Go Smart MDI system with the Simplera sensor in Europe. The system brings together data from the InPen smart insulin pen and the Simplera sensor into a single mobile app for people managing diabetes with multiple daily injections (MDI).

For investors’ note, Medtronic’s planned separation of its Diabetes business, to operate as MiniMed, is on track to be completed by the end of 2026. In December 2025, the company filed a Form S-1 with the U.S. Securities and Exchange Commission for a proposed initial public offering (IPO) of newly issued common stock, with the preferred path being an IPO followed by a split-off.

Significance of Medtronic’s MiniMed Go

The MiniMed Go Smart MDI system represents a clear shift from traditional and basic connected insulin pens. It provides real-time, personalized insights, actionable dose s, a built-in advanced dose calculator and continuous guidance — all accessible through a smartphone app. This intelligent decision support tool is designed to address daily challenges faced by those managing diabetes with MDI. The new CareLink Clinic MDI reports included make it easier for clinicians to interpret user data and support more informed patient discussions. 

In Europe, the MiniMed Go system with Simplera sensor is approved for people with insulin-requiring diabetes aged seven years and older, as well as for children aged two to six years under the supervision of an adult caregiver. The rollout will begin this month and is set to expand gradually across the region.

Compatibility of the Instinct Go sensor, made by Abbott, with MiniMed Go in Europe is currently pending CE mark approval. Once approved, users will have the choice between a seven-day or 15-day sensor depending on what best fits their needs.

More Developments Within Medtronic Diabetes

In February, the company announced three key U.S. milestones that expand access, choice, and flexibility for people with type 1 and insulin???requiring type 2 diabetes. These include FDA clearance of the MiniMed 780G system for use with ultra-rapid-acting insulins Fiasp and Lyumjev, and Medicare access for the MiniMed 780G system paired with Abbott’s Instinct sensor. The MiniMed 780G system is now cleared by the FDA for use with the Instinct sensor for insulin-requiring type 2 diabetes.

MDT’s Favorable Industry Prospects

According to Precedence Research, the global diabetes devices market is valued at $35.26 billion in 2025 and is projected to witness a CAGR of 7.7% through 2034. Key factors fueling the market’s growth include the growing prevalence of diabetes, obesity and unhealthy eating habits, technological advancements in diabetes monitoring devices and rising personal disposable income.

Updates From MDT’s Diabetes Rivals

Acton, MA-based Insulet PODD is a renowned player intubeless insulin pump technology with its Omnipod brand of products. The company’s flagship innovation, Omnipod 5 Automated Insulin Delivery System, is now available in the Middle East — including Saudi Arabia, Kuwait, Qatar and the United Arab Emirates — where unmet need remains high. Insulet has also received FDA 510(k) clearance for significant enhancements to the Omnipod 5, including a lower 100 mg/dL Target Glucose option and an enhanced algorithm designed to help users stay in Automated Mode with fewer interruptions.

Healthcare major Abbott’s ABT flagship sensor-based continuous glucose monitoring (CGM) system, FreeStyle Libre, has established a leading global position across both Type 1 and Type 2 diabetes populations.Recently, the company received FDA’s approval for its CardioMEMS HERO device — a next-generation pulmonary artery (PA) pressure reader to support people living with heart failure. Abbott also reported positive early findings from the VERITAS Study, showing meaningful closure rates of the investigational Amulet 360 Left Atrial Appendage Occluder, which is designed to reduce stroke risk in patients with non-valvular atrial fibrillation.

Tandem Diabetes Care TNDM, a pure-play diabetes technology company, closed 2025 with a milestone achievement of more than $1 billion in worldwide sales. During the year, the company introduced new technologies across the portfolio, including the Control-IQ Plus next-generation automated insulin delivery algorithm, and two highly sought-after pump features in the United States — the t:slim X2 insulin pump compatibility with Abbott’s FreeStyle Libre and Android control for Tandem Mobi. Building on this momentum, Tandem Diabetes is preparing for three additional product launches in the coming months — a scaled international rollout of Mobi, the U.S. launch of Mobi integrated with FreeStyle Libre 3 Plus and Dexcom's 15-day sensor integration on both pumps and platforms globally.